The Johnson & Johnson (Janssen) COVID-19 vaccine caused the same kinds of short-term reactions that most vaccines do: injection site pain, headache, fatigue, and muscle aches, with roughly a third to half of recipients experiencing at least one of these in clinical trials. The rare side effects, though far less common, drew intense public attention because they included unusual blood clots with low platelets, a nerve disorder called Guillain-Barré syndrome, and severe allergic reactions. These rare events ultimately led U.S. regulators to recommend mRNA vaccines over the J&J shot in late 2021, and the vaccine’s emergency use authorization was revoked in 2023.
What the Common Side Effects Looked Like
In the large Phase 3 clinical trial (known as COV3001), the most frequently reported reaction was pain at the injection site, affecting about half of participants. Systemic reactions, meaning symptoms felt throughout the body rather than just at the arm, were also widespread. Roughly four in ten people reported headache or fatigue, about a third experienced muscle aches, and around one in seven had nausea.1U.S. Food and Drug Administration. Janssen COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers – Section: 6 OVERALL SAFETY SUMMARY These numbers are broadly in line with what other COVID-19 vaccines produced, and they reflect the immune system gearing up in response to the viral protein the vaccine delivers.
Other common but less frequent reactions included fever, chills, and joint pain. Most people who experienced these side effects described them as mild to moderate. They tended to appear within the first day or two after vaccination and resolved on their own within a few days, rarely lasting beyond 72 hours. This pattern is familiar to anyone who has had a flu shot that left them feeling run-down for a day: the discomfort is real, but it is temporary and does not indicate anything dangerous is happening.
One practical detail worth knowing: because the J&J vaccine was a single-dose regimen (at least initially), recipients only went through this once. People who received the two-dose mRNA vaccines often reported stronger side effects after the second dose, so the single-shot convenience of J&J came with a slight advantage in total side-effect burden for many people. That said, when a booster dose was later recommended for J&J recipients, a second round of these common reactions followed.
Thrombosis with Thrombocytopenia Syndrome
The rare side effect that generated the most concern was thrombosis with thrombocytopenia syndrome, or TTS. This is a condition where blood clots form in unusual locations, such as the veins draining the brain (cerebral venous sinuses), the portal vein near the liver, or the splenic vein, while at the same time the blood’s platelet count drops dangerously low. The combination of clotting and low platelets is what made TTS distinctive and initially confusing to clinicians, because most clotting disorders involve high platelet activity, not low.
By late April 2021, the national vaccine safety monitoring system (VAERS) had received 15 reports of TTS following the J&J vaccine. Thirteen of those cases were in women between the ages of 18 and 49, and two were in women aged 50 or older. No confirmed post-authorization cases had been reported in men at that point.2Centers for Disease Control and Prevention. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 The strong skew toward younger women was one of the early clues that TTS was a real vaccine-associated event and not a coincidence. It also shaped initial warnings: for a period, health authorities specifically flagged the risk for women under 50.
The mechanism behind TTS appears to involve an immune reaction that produces antibodies against a protein on platelets called platelet factor 4. This is similar to what happens in heparin-induced thrombocytopenia, a known drug reaction, which is why TTS was sometimes called “vaccine-induced immune thrombocytopenia and thrombosis” (VITT) in the medical literature. Recognizing this link was important for treatment, because standard blood thinners like heparin, which would normally be the go-to for clots, could actually worsen the condition if it was driven by anti-platelet-factor-4 antibodies. Clinicians learned to use alternative anticoagulants and sometimes intravenous immunoglobulin instead.
In absolute terms, TTS remained extremely rare. Estimates varied as more data accumulated, but the rate was generally described as a handful of cases per million doses administered. Still, the severity of TTS was high when it did occur. Some cases were fatal, and others caused lasting damage from strokes or other complications of clotting in critical blood vessels. The combination of rarity and severity made TTS one of the hardest risks to communicate to the public: for any individual, the odds were vanishingly small, but the consequences could be catastrophic.
Guillain-Barré Syndrome
Guillain-Barré syndrome (GBS) is a condition in which the immune system attacks the nerves outside the brain and spinal cord, causing weakness that typically starts in the legs and can progress upward. Most people recover, but severe cases can lead to temporary paralysis and, rarely, long-term nerve damage. GBS has been associated with several types of infections and, at low rates, with certain vaccines, so regulators were watching for it from the start of the COVID-19 vaccine rollout.
A study using the Vaccine Safety Datalink, a network of large U.S. health systems, found that the incidence of confirmed GBS in the three weeks after J&J vaccination was notably higher than the background rate. The unadjusted incidence was about 32 cases per 100,000 person-years during that window, and the risk in the first three weeks after vaccination was roughly six times higher than in the following three weeks.3JAMA Network Open. Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink – Section: Results That comparison, looking at the same group of vaccinated people during two consecutive time windows, helps isolate the vaccine’s contribution from the background hum of GBS cases that occur in the general population for other reasons.
To put this in perspective, person-years is a statistical measure that accounts for both the number of people and the time they were observed. Translating the rate into something more intuitive, the excess risk amounted to a small number of additional GBS cases per million doses. As with TTS, the absolute risk to any one person was very low, but GBS is a serious enough condition that regulators added it to the vaccine’s warning label. The signal was stronger for the J&J vaccine than for the mRNA vaccines, which became another factor in the eventual preference for mRNA shots.
Severe Allergic Reactions
Anaphylaxis, the most dangerous form of acute allergic reaction, can theoretically occur after any vaccine. For the J&J vaccine, early safety monitoring found the rate to be extremely low. Of 79 initial reports of possible anaphylaxis submitted to VAERS, only four were confirmed as true anaphylaxis after medical record review, working out to fewer than half a case per million doses administered.4Centers for Disease Control and Prevention. Safety Monitoring of the Janssen COVID-19 Vaccine — United States, March–April 2021 – Section: Review of VAERS Data That rate is comparable to anaphylaxis rates seen with other common vaccines.
Confirmed anaphylaxis cases typically occurred within minutes of vaccination, which is why vaccination sites kept people for a 15- to 30-minute observation period after their shot. In every confirmed case, the reaction was treatable with epinephrine and standard emergency care. People with a known history of severe allergic reactions to any component of the vaccine were advised not to receive it, but a general history of allergies to food, pollen, or unrelated medications was not considered a reason to avoid it.
The gap between the 79 initial reports and the 4 confirmed cases highlights a common issue with passive safety monitoring: not every report that comes in turns out to be what it initially appears. VAERS collects reports from anyone, including patients themselves, and confirmation requires a clinician reviewing the case against established diagnostic criteria. This is not a flaw in the system; it is how the system is designed to work. Casting a wide net catches real signals, but it also catches false alarms that need to be sorted out.
Other Rare Events Flagged During Mass Vaccination
Beyond TTS, GBS, and anaphylaxis, the FDA’s fact sheet for the J&J vaccine listed several additional rare adverse events that were reported during post-authorization surveillance. These included immune thrombocytopenia (low platelet counts without the unusual clotting pattern seen in TTS), myocarditis and pericarditis (inflammation of the heart muscle or its surrounding sac), and capillary leak syndrome (a condition where fluid leaks from small blood vessels into surrounding tissue, causing dangerous drops in blood pressure).1U.S. Food and Drug Administration. Janssen COVID-19 Vaccine EUA Fact Sheet for Healthcare Providers – Section: 6 OVERALL SAFETY SUMMARY
Myocarditis and pericarditis attracted enormous public interest during the pandemic, though these conditions were more commonly associated with the mRNA vaccines (Pfizer and Moderna), particularly in younger males after their second dose. Cases linked to the J&J vaccine were reported but appeared to be rarer. Capillary leak syndrome was flagged partly because people who already had a history of the condition were thought to be at higher risk, and it was added as a contraindication in some regulatory jurisdictions.
With all of these rare events, an important caveat applies: being reported during post-authorization surveillance does not automatically prove the vaccine caused the condition. Surveillance systems are designed to detect possible signals, and follow-up epidemiological studies are needed to determine whether a condition occurs more often in vaccinated people than would be expected by chance. For TTS and GBS, those follow-up studies confirmed a likely causal link with the J&J vaccine. For some of the other listed events, the evidence remained thinner.
Why U.S. Regulators Shifted Their Recommendation
In December 2021, the Advisory Committee on Immunization Practices (ACIP) issued an updated recommendation stating that mRNA COVID-19 vaccines were preferred over the J&J vaccine for all adults. The committee’s reasoning was straightforward: the mRNA vaccines had both higher effectiveness against COVID-19 and a more favorable safety profile, with fewer serious rare side effects. At the same time, ACIP emphasized that the J&J vaccine’s benefits still outweighed the risks of remaining unvaccinated, acknowledging that some people might only have access to the J&J shot or might have medical reasons to avoid mRNA vaccines.5Centers for Disease Control and Prevention. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021
ACIP also raised an equity concern that often got lost in media coverage: if the J&J vaccine was disproportionately directed toward harder-to-reach populations (homeless individuals, people in rural areas with limited cold-chain storage for mRNA vaccines, incarcerated populations), those groups would bear a disproportionate share of the rare risks. The committee explicitly flagged that an inequitable distribution of TTS and GBS risk could result from such patterns.5Centers for Disease Control and Prevention. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021 This was a rare instance of a vaccine advisory body incorporating distributional justice into a clinical recommendation, and it reflected the unusual situation of having multiple effective vaccines available at the same time.
By mid-2023, the J&J vaccine’s emergency use authorization in the United States was revoked. This did not happen because a dramatic new safety signal emerged but because the combination of lower demand, the availability of updated mRNA vaccines, and the accumulated safety data made the risk-benefit calculation no longer favorable enough to justify keeping it on the market. In other parts of the world, versions of the same adenoviral vector platform continued to be used under different regulatory frameworks.
Adenoviral Vector Vaccines and the Pattern Across Platforms
The J&J vaccine used an adenovirus (a modified cold virus) to deliver the genetic instructions for the SARS-CoV-2 spike protein into cells. The AstraZeneca vaccine, widely used outside the United States, employed a similar adenoviral vector approach with a different adenovirus. Both vaccines were linked to TTS, which suggested that the rare clotting complication was related to the adenoviral vector platform itself rather than being unique to one manufacturer’s product. This pattern was part of what made the evidence for a causal link between adenoviral vector COVID vaccines and TTS so persuasive, even when the absolute numbers were small.
The mRNA vaccines (Pfizer-BioNTech and Moderna) use an entirely different delivery mechanism and were not linked to TTS. They had their own rare side-effect profile, most prominently myocarditis in young males, but the clotting-with-low-platelets pattern was absent. For regulators, this divergence between platforms was informative: it pointed to the delivery vehicle, not the spike protein payload, as the likely trigger for TTS. Understanding this distinction mattered for future vaccine development, because adenoviral vectors are used in vaccines for other diseases as well, including Ebola, and knowing which platform carries which rare risk helps manufacturers and regulators plan accordingly.
For anyone who received the J&J vaccine during the period it was available, the window for common side effects closed within days and the window for rare events like TTS (which typically appeared within the first two weeks) has long since passed. GBS cases similarly clustered in the first few weeks after vaccination. There is no evidence that any of these rare complications have a delayed-onset pattern stretching months or years after the shot. If you got the J&J vaccine and felt fine after the first month, the data strongly suggest you are in the clear.